India clears Roche’s 7-minute cancer injection Tecentriq for patients, with Phase IV trial condition
Roche has received clearance to import and market Atezolizumab injection (Tecentriq) for subcutaneous administration in India, potentially reducing cancer treatment time and costs. The approval, granted by a technical committee, requires Roche to conduct a Phase IV clinical trial in India. This new route offers a faster, more convenient option for patients, with administration possible outside of hospitals.
